Y Intercept Hong Kong Ltd Makes New $243,000 Investment in Anavex Life Sciences Corp. (NASDAQ:AVXL)

Y Intercept Hong Kong Ltd bought a new position in shares of Anavex Life Sciences Corp. (NASDAQ:AVXL) during the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor bought 22,631 shares of the biotechnology company’s stock, valued at approximately $243,000.

A number of other large investors also recently modified their holdings of AVXL. Geode Capital Management LLC raised its stake in Anavex Life Sciences by 2.8% during the third quarter. Geode Capital Management LLC now owns 1,883,199 shares of the biotechnology company’s stock worth $10,699,000 after acquiring an additional 51,946 shares during the period. Nwam LLC bought a new position in shares of Anavex Life Sciences during the third quarter valued at approximately $5,172,000. Charles Schwab Investment Management Inc. raised its position in shares of Anavex Life Sciences by 2.3% during the 3rd quarter. Charles Schwab Investment Management Inc. now owns 665,976 shares of the biotechnology company’s stock worth $3,783,000 after purchasing an additional 14,892 shares during the period. Barclays PLC lifted its holdings in shares of Anavex Life Sciences by 70.4% in the 3rd quarter. Barclays PLC now owns 155,179 shares of the biotechnology company’s stock worth $882,000 after purchasing an additional 64,101 shares during the last quarter. Finally, Rhumbline Advisers boosted its position in Anavex Life Sciences by 2.9% during the 4th quarter. Rhumbline Advisers now owns 123,699 shares of the biotechnology company’s stock valued at $1,329,000 after purchasing an additional 3,498 shares during the period. 31.55% of the stock is currently owned by institutional investors.

Wall Street Analyst Weigh In

A number of equities research analysts have issued reports on AVXL shares. D. Boral Capital reiterated a “buy” rating and issued a $46.00 target price on shares of Anavex Life Sciences in a research note on Wednesday, February 12th. HC Wainwright reiterated a “buy” rating and issued a $42.00 price objective on shares of Anavex Life Sciences in a research report on Tuesday, February 18th.

Anavex Life Sciences Price Performance

Shares of Anavex Life Sciences stock opened at $8.41 on Wednesday. Anavex Life Sciences Corp. has a 1-year low of $3.25 and a 1-year high of $14.44. The business’s fifty day moving average price is $9.83 and its two-hundred day moving average price is $7.88. The company has a market capitalization of $715.39 million, a P/E ratio of -15.29 and a beta of 0.69.

Anavex Life Sciences (NASDAQ:AVXL) last posted its quarterly earnings data on Wednesday, February 12th. The biotechnology company reported ($0.14) earnings per share for the quarter, topping the consensus estimate of ($0.17) by $0.03. On average, research analysts expect that Anavex Life Sciences Corp. will post -0.69 earnings per share for the current fiscal year.

Anavex Life Sciences Company Profile

Anavex Life Sciences Corp., a clinical stage biopharmaceutical company, engages in the development of therapeutics for the treatment of central nervous system diseases. Its lead product candidate is ANAVEX 2-73 for the treatment of Alzheimer's disease and Parkinson's disease, as well as other central nervous system diseases, including rare diseases, such as Rett syndrome, a rare severe neurological monogenic disorder; and infantile spasms, Fragile X syndrome, and Angelman syndrome.